- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1e1cac62-ce64-4dc8-8fe8-5fb7c3289bea&Preview=1 - Date
11/21/2011 - Company Name
NormOxys - Mailing Address
16 Laurel Ave. Wellesley, MA 02481 - Company Description
NormOxys is developing a novel class of small molecule drugs, oxyrens, which enhance the body’s ability to deliver oxygen more efficiently to diseased tissues with oxygen deficiency. This new class of drugs can be potentially developed in a broad range of clinical indications where therapeutic benefit can be obtained through an increased, regulated delivery of oxygen to hypoxic tissues, such as cancer, cardiovascular diseases, anemia, stroke and diabetic retinopathy. - Website
http://www.normoxys.com - Transaction Type
Debt - Transaction Amount
$600,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. Secured convertible promissory notes. SEC regulatory filing. - M&A Terms
- Venture Investor
Undisclosed